���重受体激动剂的分子设计 — Reference Sheet

By Editorial Desk · published 2026-06-11 · last reviewed 2026-07-31 · Info

Everything below concerns 肽类药物. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-07-31. Where a claim depends on a specific study, the study is described rather than over-claimed.

三重受体激动剂的分子设计

该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。

retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。

Discovery and Receptor Profile

Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.

Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.

Retatrutide at a glance

Further detail

== Treatment == The major emphasis of the treatment of JIA is helping the child or young person regain normal levels of physical and social functioning by controlling inflammation and extra-articular symptoms. Clinical remission should be the primary target for all people. Prompt recognition and management is important as early initiation of medication therapy increases the likelihood of a response to first-line treatments and low disability. Consensus treatment guidelines exist for the treatment of JIA. Optimal management of JIA requires a multidisciplinary team working to address the needs of an individual child. Optimizing physical and social functioning is accomplished using non-pharmacological strategies such as physical therapies, pain management strategies, and social supports. Medications are used to control inflammation and reduce or prevent extra-articular symptoms.Non-steroidal anti-inflammatory drugs (NSAIDs) are used for symptomatic relief of joint pain in children with JIA. Disease-modifying antirheumatic drugs (DMARDs), which inhibit specific pathways in the inflammation pathways responsible for JIA, are a primary treatment. Lifelong DMARD treatment is often required, and drug-free remission is exceedingly rare. Oligoarticular JIA (which comprises 40-50% of all JIA cases) by definition involves 4 or fewer joints in the first 6 months of the disease. After 6 months, some cases become polyarticular (involving more than 4 joints). This polyarticular subtype is associated with a lower remission rate with medical therapy.

==== Eastern copperhead ==== The eastern copperhead (Agkistrodon contortrix) is a species of venomous snake, a pit viper, endemic to eastern North America; it is a member of the subfamily Crotalinae in the family Viperidae. The generic name is derived from the Greek words ancistro (hooked) and odon (tooth), and the specific name comes from the Latin contortus (twisted, intricate, complex); thus, the scientific name translates into "twisted hook-tooth".

== 1960 attempted coup and disbandment == "It remained the elite force of the empire," notes historian Bahru Zewde, "until discredited in the wake of the attempted coup of 1960." That unsuccessful coup had been planned by its commander Brigadier-General Mengistu Neway, and his brother Germame Neway. In 1961, it numbered nine battalions; in 1969 some 7,000 men. In 1974, the Commander was Major-General Tafessa Lemma. The Kebur Zabagna was disbanded after the Derg consolidated their hold on Ethiopia. After the Imperial Bodyguard attempted to overthrow the Emperor in 1962 its most lethal element, the Berari Neber whose paratroopers had just completed training and received their wings from the Emperor a bare 2 months earlier were separated and attached to the regular army. The men selected out of the Berari-Nebir were responsible for the anti-hijack program. The Anti-Hijack program interdicted about 4 hijack attempts. In the most famous one of these was in 1972 when Wallelign Mekonnen with ELF (Eritrean Liberation Front) trained operatives led a 3 man 2 women cell in an abortive attempt to hijack an Ethiopian airlines Boeing 707. They reportedly smuggled 1 grenade and 1 handgun on the plane in the women's underpants. Ethiopian anti-Hijack commandos shot and killed two hijackers and the rest were killed by a bomb they set off.

=== Selected articles === Townsend, D. M., Tew, K. D., & Tapiero, H. (2003). The importance of glutathione in human disease. Biomedicine & pharmacotherapy, 57(3-4), 145–155. Townsend, D. M., & Tew, K. D. (2003). The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene, 22(47), 7369–7375. Townsend, D. M., Deng, M., Zhang, L., Lapus, M. G., & Hanigan, M. H. (2003). Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. Journal of the American Society of Nephrology: JASN, 14(1), 1. Tapiero, H., Townsend, D. M., & Tew, K. D. (2004). The role of carotenoids in the prevention of human pathologies. Biomedicine & Pharmacotherapy, 58(2), 100–110. Grek, C. L., Zhang, J., Manevich, Y., Townsend, D. M., & Tew, K. D. (2013). Causes and consequences of cysteine S-glutathionylation. Journal of Biological Chemistry, 288(37), 26497–26504.

===== United Kingdom ===== In the UK, semaglutide is available on NHS prescription for diabetes at nominal or no cost to the individual. It is also available for obesity, limited to treatment for two years.

Sources: en.wikipedia.org

Related pages on this site

• Practical summary
• Measured briefing
• Gradual workbook
• Simple dataset
• Automated report
• Proven review
• Seasonal digest
• Simple overview

Supporting material

=== DNA uptake mechanism === When DNA uptake and subsequent expression was first demonstrated in vivo in muscle cells, these cells were thought to be unique because of their extensive network of T-tubules. Using electron microscopy, it was proposed that DNA uptake was facilitated by caveolae (or, non-clathrin coated pits). However, subsequent research revealed that other cells (such as keratinocytes, fibroblasts and epithelial Langerhans cells) could also internalize DNA. The mechanism of DNA uptake is not known. Two theories dominate – that in vivo uptake of DNA occurs non-specifically, in a method similar to phago- or pinocytosis, or through specific receptors. These might include a 30kDa surface receptor, or macrophage scavenger receptors. The 30kDa surface receptor binds specifically to 4500-bp DNA fragments (which are then internalised) and is found on professional APCs and T-cells. Macrophage scavenger receptors bind to a variety of macromolecules, including polyribonucleotides and are thus candidates for DNA uptake. Receptor-mediated DNA uptake could be facilitated by the presence of polyguanylate sequences. Gene gun delivery systems, cationic liposome packaging, and other delivery methods bypass this entry method, but understanding it may be useful in reducing costs (e.g. by reducing the requirement for cytofectins), which could be important in animal husbandry.

Grover CN, Cameron RE, Best SM: Investigating the morphological, mechanical and degradation properties of scaffolds comprising collagen, gelatin and elastin for use in soft tissue engineering. J Mech Behav Biomed Mater. 2012 Jun;10:62-74.

==== Miscellaneous ==== Buspirone is not effective as a treatment for benzodiazepine withdrawal, barbiturate withdrawal, or alcohol withdrawal. SSRI and SNRI antidepressants such as paroxetine and venlafaxine, respectively, may cause jaw pain/jaw spasm reversible syndrome, although it is not common, and buspirone appears to be successful in treating antidepressant-induced bruxism.

CSL has developed antivenoms for the redback spider, funnel-web spiders and all deadly Australian snakes. In the USA, the H.K. Mulford company began producing "Nearctic Crotalidae antivenin" in 1927, via a consortium called the Antivenin Institute of America. Over time, a variety of improvements have been made in the specificity, potency, and purity of antivenom products, including "salting out" with ammonium sulphate or caprylic acid, enzymatic reduction of antibodies with papain or with pepsin, affinity purification, and a variety of other measures. Many equine facilities now use plasmapheresis to collect blood plasma instead of blood serum.

=== BioCompute and BioCompute Objects === In 2014, the US Food and Drug Administration sponsored a conference held at the National Institutes of Health Bethesda Campus to discuss reproducibility in bioinformatics. Over the next three years, a consortium of stakeholders met regularly to discuss what would become BioCompute paradigm. These stakeholders included representatives from government, industry, and academic entities. Session leaders represented numerous branches of the FDA and NIH Institutes and Centers, non-profit entities including the Human Variome Project and the European Federation for Medical Informatics, and research institutions including Stanford, the New York Genome Center, and the George Washington University. It was decided that the BioCompute paradigm would be in the form of digital 'lab notebooks' which allow for the reproducibility, replication, review, and reuse, of bioinformatics protocols. This was proposed to enable greater continuity within a research group over the course of normal personnel flux while furthering the exchange of ideas between groups. The US FDA funded this work so that information on pipelines would be more transparent and accessible to their regulatory staff. In 2016, the group reconvened at the NIH in Bethesda and discussed the potential for a BioCompute Object, an instance of the BioCompute paradigm. This work was copied as both a "standard trial use" document and a preprint paper uploaded to bioRxiv. The BioCompute object allows for the JSON-ized record to be shared among employees, collaborators, and regulators.

Sources: en.wikipedia.org

Frequently asked questions